p-Chloroaniline hydrochloride


Literature identifierStudy typeTest dosageEffective dosageEndocrine-mediated endpointsSystems-level perturbations
PMID:2010141IVR2 mg/kg 2 mg/kgChanges in spleen morphologyImmunological endocrine-mediated perturbations
IVR2 mg/kg 2 mg/kgHyperplasia of bone marrowImmunological endocrine-mediated perturbations
IVR2 mg/kg 2 mg/kgHematopietic carcinomaEndocrine-mediated cancer;Immunological endocrine-mediated perturbations
IVR6 mg/kg 6 mg/kgChanges in spleen morphologyImmunological endocrine-mediated perturbations
IVR6 mg/kg 6 mg/kgHematopietic carcinomaEndocrine-mediated cancer;Immunological endocrine-mediated perturbations
IVR6 mg/kg 6 mg/kgHyperplasia of bone marrowImmunological endocrine-mediated perturbations
IVR18 mg/kg 18 mg/kgHematopietic carcinomaEndocrine-mediated cancer;Immunological endocrine-mediated perturbations
IVR18 mg/kg 18 mg/kgHyperplasia in adrenal glandMetabolic endocrine-mediated perturbations
IVR18 mg/kg 18 mg/kgHyperplasia of bone marrowImmunological endocrine-mediated perturbations
IVR18 mg/kg 18 mg/kgChanges in spleen morphologyImmunological endocrine-mediated perturbations

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.